Skip to main content



) --

Novo Nordisk A/S



) hit a new 52-week high Thursday as it is currently trading at $142.04, above its previous 52-week high of $140.50 with 112,607 shares traded as of 11:19 a.m. ET. Average volume has been 268,500 shares over the past 30 days.

Novo Nordisk A/S has a market cap of $68.43 billion and is part of the

health care

sector and


industry. Shares are up 20.6% year to date as of the close of trading on Wednesday.

Scroll to Continue

TheStreet Recommends

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The company has a P/E ratio of four, below the average drugs industry P/E ratio of 22.5 and below the S&P 500 P/E ratio of 17.7.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Novo Nordisk A/S as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full

Novo Nordisk A/S Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center